Idefirix

Imlifidase, the active ingredient in Idefirix, is an IgG‑degrading enzyme presented as an intravenous formulation for intravenous use. It is employed to reduce circulating IgG antibodies and facilitate desensitization in highly sensitized kidney transplant recipients. GNH USA supplies Idefirix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Idefirix is used in the transplant immunology pathway to lower antibody‑mediated rejection risk.

Kidney transplant desensitization: enables highly sensitized recipients to receive a compatible donor organ by rapidly reducing circulating IgG antibodies.

Idefirix may cause a range of adverse reactions following intravenous administration.

Common Side Effects: - Infusion‑related reactions: flushing, rash, or mild hypotension. - Headache or dizziness. - Nausea, vomiting, or abdominal discomfort. - Fever or chills. - Transient fatigue.

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction. - Cytokine release syndrome with high fever and hypotension. - Thromboembolic events such as deep‑vein thrombosis. - Hemolysis or immune‑complex mediated disease. - Severe infection due to profound IgG depletion.

Prior to initiating Idefirix therapy, several safety considerations should be observed. - Assess IgG levels: monitor baseline and post‑infusion concentrations. - Screen for active infections: avoid use in uncontrolled bacterial, viral, or fungal infections. - Evaluate renal function: ensure appropriate monitoring in transplant recipients. - Avoid in patients with known hypersensitivity to the enzyme or its excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idefirix can interact with other medicines that affect immune function or hemostasis.

Major Interactions (Avoid): - Concurrent IgG‑depleting agents: may cause excessive immunosuppression. - Live vaccines: increased risk of vaccine‑derived infection. - Strong immunosuppressants (e.g., calcineurin inhibitors): heightened infection susceptibility.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, heparin): monitor bleeding parameters. - Corticosteroids: may mask infusion‑related reactions. - Cytokine modulators (e.g., tocilizumab): could alter the therapeutic response.